Physician profile
Joy Catherine Tomko
NPI 1366771024
$2,358.92
in general payments reported to CMS, 2019-2025
23 companies · $507 in 2025
The $507 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $300 · 2021: $71.31 · 2022: $346 · 2023: $457 · 2024: $230 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $429.19 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $367.48 | 2023-2025 | Miebo, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $294.81 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $160.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $133.56 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.91 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $124.27 | 2019-2023 | Acuvue |
| New World Medical,INC. | $123.77 | 2023 | |
| Dompe US, INC. | $117.43 | 2024-2025 | Oxervate |
| Allergan, INC. | $107.41 | 2019 | |
| Abbvie INC. | $66.15 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $61.51 | 2019-2022 | |
| Coopervision INC. | $42.02 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $37.91 | 2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Alcon Vision LLC | $27.40 | 2025 | Rocklatan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $25.55 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $20.52 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.81 | 2024 | Syfovre |
| Biotissue Holdings INC. | $18.09 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $15.05 | 2020 | |
| Omeros Corporation | $14.18 | 2019 | |
| Abb Con-Cise Optical Group LLC | $10.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Tomko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.